Literature DB >> 16461355

Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by fatty acid amide hydrolase.

Martin Kaczocha1, Anita Hermann, Sherrye T Glaser, Inge N Bojesen, Dale G Deutsch.   

Abstract

The uptake of arachidonoyl ethanolamide (anandamide, AEA) in rat basophilic leukemia cells (RBL-2H3) has been proposed to occur via a saturable transporter that is blocked by specific inhibitors. Measuring uptake at 25 s, when fatty acid amide hydrolase (FAAH) does not appreciably affect uptake, AEA accumulated via a nonsaturable mechanism at 37 degrees C. Interestingly, saturation was observed when uptake was plotted using unbound AEA at 37 degrees C. Such apparent saturation can be explained by rate-limited delivery of AEA through an unstirred water layer surrounding the cells (1). In support of this, we observed kinetics consistent with rate-limited diffusion at 0 degrees C. Novel transport inhibitors have been synthesized that are either weak FAAH inhibitors or do not inhibit FAAH in vitro (e.g. UCM707, OMDM2, and AM1172). In the current study, none of these purported AEA transporter inhibitors affected uptake at 25 s. Longer incubation times illuminate downstream events that drive AEA uptake. Unlike the situation at 25 s, the efficacy of these inhibitors was unmasked at 5 min with appreciable inhibition of AEA accumulation correlating with partial inhibition of AEA hydrolysis. The uptake and hydrolysis profiles observed with UCM707, VDM11, OMDM2, and AM1172 mirrored two selective and potent FAAH inhibitors CAY10400 and URB597 (at low concentrations), indicating that weak inhibition of FAAH can have a pronounced effect upon AEA uptake. At 5 min, the putative transport inhibitors did not reduce AEA uptake in FAAH chemical knock-out cells. This strongly suggests that the target of UCM707, VDM11, OMDM2, and AM1172 is not a transporter at the plasma membrane but rather FAAH, or an uncharacterized intracellular component that delivers AEA to FAAH. This system is therefore unique among neuro/immune modulators because AEA, an uncharged hydrophobic molecule, diffuses into cells and partial inhibition of FAAH has a pronounced effect upon its uptake.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16461355     DOI: 10.1074/jbc.M509721200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  Pitfalls and solutions in assaying anandamide transport in cells.

Authors:  Sergio Oddi; Filomena Fezza; Giuseppina Catanzaro; Chiara De Simone; Mariangela Pucci; Daniele Piomelli; Alessandro Finazzi-Agrò; Mauro Maccarrone
Journal:  J Lipid Res       Date:  2010-05-06       Impact factor: 5.922

Review 2.  Adenosine-cannabinoid receptor interactions. Implications for striatal function.

Authors:  Sergi Ferré; Carme Lluís; Zuzana Justinova; César Quiroz; Marco Orru; Gemma Navarro; Enric I Canela; Rafael Franco; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

3.  Inhibition of the cellular uptake of anandamide by genistein and its analogue daidzein in cells with different levels of fatty acid amide hydrolase-driven uptake.

Authors:  L Thors; J Eriksson; C J Fowler
Journal:  Br J Pharmacol       Date:  2007-08-06       Impact factor: 8.739

4.  Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.

Authors:  Amy K Dickason-Chesterfield; Stephanie R Kidd; Steven A Moore; John M Schaus; Bin Liu; George G Nomikos; Christian C Felder
Journal:  Cell Mol Neurobiol       Date:  2006-05-31       Impact factor: 5.046

Review 5.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

Review 6.  Enzymatic pathways that regulate endocannabinoid signaling in the nervous system.

Authors:  Kay Ahn; Michele K McKinney; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2008-04-23       Impact factor: 60.622

7.  Evidence for bidirectional endocannabinoid transport across cell membranes.

Authors:  Andrea Chicca; Janine Marazzi; Simon Nicolussi; Jürg Gertsch
Journal:  J Biol Chem       Date:  2012-08-09       Impact factor: 5.157

Review 8.  Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.

Authors:  V Kiran Vemuri; David R Janero; Alexandros Makriyannis
Journal:  Physiol Behav       Date:  2007-11-21

Review 9.  Cannabinoids and multiple sclerosis.

Authors:  Roger G Pertwee
Journal:  Mol Neurobiol       Date:  2007-06-26       Impact factor: 5.590

Review 10.  The pharmacology of the cannabinoid system--a question of efficacy and selectivity.

Authors:  Christopher J Fowler
Journal:  Mol Neurobiol       Date:  2007-07-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.